IMV Inc. (NASDAQ:IMV) shares traded 8.00% higher at $3.51 on Wall Street last session.
In accordance with the data, 5 analysts cover IMV Inc. (NASDAQ:IMV). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $65.00 and a low of $22.50, we find $40.00. Given the previous closing price of $3.25, this indicates a potential upside of 1130.77 percent. IMV stock price is now 22.80% away from the 50-day moving average and -47.35% away from the 200-day moving average. The market capitalization of the company currently stands at $33.10M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 0 analysts and a buy by 5. Brokers who have rated the stock have averaged $44.88 as their price target over the next twelve months.
With the price target of $4, Cantor Fitzgerald recently initiated with Overweight rating for IMV Inc. (NASDAQ: IMV). , while ‘B. Riley FBR’ rates the stock as ‘Neutral’.
A total of 0.56% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IMV stock. A new stake in IMV Inc. shares was purchased by JPMORGAN CHASE & CO during the first quarter worth $11,000. MILLENNIUM MANAGEMENT LLC invested $4,000 in shares of IMV during the first quarter. In total, there are 44 active investors with 23.35% ownership of the company’s stock.
IMV Inc. (NASDAQ: IMV) opened at $3.1300 on Tuesday. During the past 12 months, IMV Inc. has had a low of $2.03 and a high of $15.30. The fifty day moving average price for IMV is $2.8586 and a two-hundred day moving average price translates $6.6111 for the stock.
The latest earnings results from IMV Inc. (NASDAQ: IMV) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.12, inline with analysts’ expectations of -$0.12. This compares to -$1.32 EPS in the same period last year. The company reported revenue of $0.12 million for the quarter, compared to $41000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 187.8 percent. For the current quarter, analysts expect IMV to generate $20k in revenue.
IMV Inc.(IMV) Company Profile
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
